Patents by Inventor Shawn E.R. SCHILLER

Shawn E.R. SCHILLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS
    Publication number: 20240150349
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Application
    Filed: September 8, 2023
    Publication date: May 9, 2024
    Applicant: FORMA Therapeutics, Inc.
    Inventors: Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230416248
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: November 10, 2021
    Publication date: December 28, 2023
    Inventors: Kevin J. WILSON, Solymar NEGRETTI, Shawn E.R. SCHILLER, Rishi G. VASWANI, David S. HUANG, Johannes H. VOIGT
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230365560
    Abstract: The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
    Type: Application
    Filed: May 11, 2023
    Publication date: November 16, 2023
    Inventors: Shawn E.R. SCHILLER, Solymar NEGRETTI, David S. HUANG, Kevin J. WILSON, Melek Nihan UCISIK, Richard CALDWELL
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230348452
    Abstract: The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: November 2, 2023
    Inventors: Matthew NETHERTON, Shawn E.R. SCHILLER, Jing DENG, Neville John ANTHONY, Francois BRUCELLE, Sabine K. RUPPEL, Johannes H. VOIGT
  • Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
    Patent number: 11787803
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: October 17, 2023
    Assignee: Forma Therapeutics, Inc.
    Inventors: Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230149414
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 18, 2023
    Inventors: Neville John ANTHONY, Rishi G. VASWANI, David Simon MILLAN, Shawn E.R. SCHILLER, Kevin J. WILSON
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230145003
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 11, 2023
    Inventors: Kevin J. WILSON, Shawn E.R. SCHILLER, Solymar NEGRETTI
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230138480
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: October 13, 2022
    Publication date: May 4, 2023
    Inventors: Neville John ANTHONY, David Simon MILLAN, Rishi G. VASWANI, Shawn E.R. SCHILLER
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230121497
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 20, 2023
    Inventors: Rishi G. VASWANI, David S. HUANG, Kevin J. WILSON, Shawn E.R. SCHILLER, Neville John ANTHONY
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230079819
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 16, 2023
    Inventors: Rishi G. VASWANI, Neville John ANTHONY, David Simon MILLAN, Shawn E.R. SCHILLER, Kevin J. WILSON, David S. HUANG
  • TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS
    Publication number: 20230061891
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.
    Type: Application
    Filed: July 23, 2021
    Publication date: March 2, 2023
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot
  • Compounds and uses thereof
    Patent number: 11497752
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: November 15, 2022
    Assignee: Foghorn Therapeutics Inc.
    Inventors: Neville John Anthony, David Simon Millan, Rishi G. Vaswani, Shawn E. R. Schiller
  • INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
    Publication number: 20220213089
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 7, 2022
    Inventors: Shawn E.R. SCHILLER, Torsten HERBERTZ, Hongbin LI, Bradford GRAVES, Steven MISCHKE, Angela V. WEST, Anna ERICSSON, Jennifer R. DOWNING
  • TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS
    Publication number: 20220169647
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Application
    Filed: February 10, 2022
    Publication date: June 2, 2022
    Inventors: Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
  • INHIBITING CREB BINDING PROTEIN (CBP)
    Publication number: 20220162207
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Application
    Filed: February 10, 2022
    Publication date: May 26, 2022
    Inventors: Shawn E.R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela West, Jennifer R. Downing, Anna Ericsson
  • Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
    Patent number: 11325917
    Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4?, R5, R6, X, and n are described herein.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: May 10, 2022
    Assignee: VALO HEALTH, INC.
    Inventors: David Joseph Guerin, Kenneth W. Bair, Justin A. Caravella, Stephanos Ioannidis, David R. Lancia, Jr., Hongbin Li, Steven Mischke, Pui Yee Ng, David Richard, Shawn E. R. Schiller, Tatiana Shelekhin, Zhongguo Wang
  • COMPOUNDS AND USES THEREOF
    Publication number: 20220119378
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2020
    Publication date: April 21, 2022
    Inventors: Neville John ANTHONY, Rishi G. VASWANI, David Simon MILLAN, Shawn E.R. SCHILLER
  • Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
    Patent number: 11292791
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: April 5, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
  • Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
    Patent number: 11267805
    Abstract: The present disclosure reports solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone:
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: March 8, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: George P. Luke, Stephen Hubbs, Matthew W. Martin, Shawn E. R. Schiller, Robert Wenslow, Yawei Shi, Jun Huang
  • Inhibiting CREB binding protein (CBP)
    Patent number: 11254674
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: February 22, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela West, Jennifer R. Downing, Anna Ericsson